Selected research
Industry Research
Neuroprotective Products Industry Research Report 2026
Market perspective
The global Neuroprotective Products market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Neuroprotective Products is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Neuroprotective Products is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Neuroprotective Products is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Neuroprotective Products include Teva Pharmaceutical Industries Ltd, Novartis, Merck KGaA, Pfizer Inc, GlaxoSmithKline plc., Biogen, AstraZeneca, Sunovion Pharmaceuticals Inc and NeuroVive Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Neuroprotective Products market in terms of revenue (US$ million) and, where applicable, sales volume (tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Neuroprotective Products Market by Company
Teva Pharmaceutical Industries Ltd
Novartis
Merck KGaA
Pfizer Inc
GlaxoSmithKline plc.
Biogen
AstraZeneca
Sunovion Pharmaceuticals Inc
NeuroVive Pharmaceutical
Neuren Pharmaceuticals
Hikma Pharmaceuticals PLC
Genervon Biopharmaceuticals
Ceregene
Bionure
Bioniz Theraputics.
BHR Pharma
Allon therapeutics
Neuroprotective Products Segment by Type
Cholinesterase inhibitors
NMDA receptor antagonists
Others
Neuroprotective Products Segment by Application
Alzheimer's disease
Multiple sclerosis
Others
Neuroprotective Products Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroprotective Products market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neuroprotective Products and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroprotective Products.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Neuroprotective Products manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Neuroprotective Products by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Neuroprotective Products in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Cholinesterase inhibitors
- NMDA receptor antagonists
- Others
Applications
- Alzheimer's disease
- Multiple sclerosis
- Others
Companies covered
- Teva Pharmaceutical Industries Ltd
- Novartis
- Merck KGaA
- Pfizer Inc
- GlaxoSmithKline plc.
- Biogen
- AstraZeneca
- Sunovion Pharmaceuticals Inc
- NeuroVive Pharmaceutical
- Neuren Pharmaceuticals
- Hikma Pharmaceuticals PLC
- Genervon Biopharmaceuticals
- Ceregene
- Bionure
- Bioniz Theraputics.
- BHR Pharma
- Allon therapeutics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Neuroprotective Products Market Size (2021-2032)
- 2.2.2 Global Neuroprotective Products Sales (2021-2032)
- 2.2.3 Global Neuroprotective Products Market Average Price (2021-2032)
- 2.3 Neuroprotective Products by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Cholinesterase inhibitors
- 2.3.3 NMDA receptor antagonists
- 2.3.4 Others
- 2.4 Neuroprotective Products by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Alzheimer's disease
- 2.4.3 Multiple sclerosis
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Neuroprotective Products Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Neuroprotective Products Sales (tons) of Manufacturers (2021-2026)
- 3.3 Global Neuroprotective Products Revenue of Manufacturers (2021-2026)
- 3.4 Global Neuroprotective Products Average Price by Manufacturers (2021-2026)
- 3.5 Global Neuroprotective Products Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Neuroprotective Products, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Neuroprotective Products, Product Type & Application
- 3.8 Global Manufacturers of Neuroprotective Products, Established Date
- 3.9 Global Neuroprotective Products Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva Pharmaceutical Industries Ltd
- 4.1.1 Teva Pharmaceutical Industries Ltd Company Information
- 4.1.2 Teva Pharmaceutical Industries Ltd Business Overview
- 4.1.3 Teva Pharmaceutical Industries Ltd Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Pharmaceutical Industries Ltd Neuroprotective Products Product Portfolio
- 4.1.5 Teva Pharmaceutical Industries Ltd Recent Developments
- 4.2 Novartis
- 4.2.1 Novartis Company Information
- 4.2.2 Novartis Business Overview
- 4.2.3 Novartis Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novartis Neuroprotective Products Product Portfolio
- 4.2.5 Novartis Recent Developments
- 4.3 Merck KGaA
- 4.3.1 Merck KGaA Company Information
- 4.3.2 Merck KGaA Business Overview
- 4.3.3 Merck KGaA Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Merck KGaA Neuroprotective Products Product Portfolio
- 4.3.5 Merck KGaA Recent Developments
- 4.4 Pfizer Inc
- 4.4.1 Pfizer Inc Company Information
- 4.4.2 Pfizer Inc Business Overview
- 4.4.3 Pfizer Inc Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Pfizer Inc Neuroprotective Products Product Portfolio
- 4.4.5 Pfizer Inc Recent Developments
- 4.5 GlaxoSmithKline plc.
- 4.5.1 GlaxoSmithKline plc. Company Information
- 4.5.2 GlaxoSmithKline plc. Business Overview
- 4.5.3 GlaxoSmithKline plc. Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 GlaxoSmithKline plc. Neuroprotective Products Product Portfolio
- 4.5.5 GlaxoSmithKline plc. Recent Developments
- 4.6 Biogen
- 4.6.1 Biogen Company Information
- 4.6.2 Biogen Business Overview
- 4.6.3 Biogen Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Biogen Neuroprotective Products Product Portfolio
- 4.6.5 Biogen Recent Developments
- 4.7 AstraZeneca
- 4.7.1 AstraZeneca Company Information
- 4.7.2 AstraZeneca Business Overview
- 4.7.3 AstraZeneca Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 AstraZeneca Neuroprotective Products Product Portfolio
- 4.7.5 AstraZeneca Recent Developments
- 4.8 Sunovion Pharmaceuticals Inc
- 4.8.1 Sunovion Pharmaceuticals Inc Company Information
- 4.8.2 Sunovion Pharmaceuticals Inc Business Overview
- 4.8.3 Sunovion Pharmaceuticals Inc Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Sunovion Pharmaceuticals Inc Neuroprotective Products Product Portfolio
- 4.8.5 Sunovion Pharmaceuticals Inc Recent Developments
- 4.9 NeuroVive Pharmaceutical
- 4.9.1 NeuroVive Pharmaceutical Company Information
- 4.9.2 NeuroVive Pharmaceutical Business Overview
- 4.9.3 NeuroVive Pharmaceutical Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 NeuroVive Pharmaceutical Neuroprotective Products Product Portfolio
- 4.9.5 NeuroVive Pharmaceutical Recent Developments
- 4.10 Neuren Pharmaceuticals
- 4.10.1 Neuren Pharmaceuticals Company Information
- 4.10.2 Neuren Pharmaceuticals Business Overview
- 4.10.3 Neuren Pharmaceuticals Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Neuren Pharmaceuticals Neuroprotective Products Product Portfolio
- 4.10.5 Neuren Pharmaceuticals Recent Developments
- 4.11 Hikma Pharmaceuticals PLC
- 4.11.1 Hikma Pharmaceuticals PLC Company Information
- 4.11.2 Hikma Pharmaceuticals PLC Business Overview
- 4.11.3 Hikma Pharmaceuticals PLC Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Hikma Pharmaceuticals PLC Neuroprotective Products Product Portfolio
- 4.11.5 Hikma Pharmaceuticals PLC Recent Developments
- 4.12 Genervon Biopharmaceuticals
- 4.12.1 Genervon Biopharmaceuticals Company Information
- 4.12.2 Genervon Biopharmaceuticals Business Overview
- 4.12.3 Genervon Biopharmaceuticals Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Genervon Biopharmaceuticals Neuroprotective Products Product Portfolio
- 4.12.5 Genervon Biopharmaceuticals Recent Developments
- 4.13 Ceregene
- 4.13.1 Ceregene Company Information
- 4.13.2 Ceregene Business Overview
- 4.13.3 Ceregene Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Ceregene Neuroprotective Products Product Portfolio
- 4.13.5 Ceregene Recent Developments
- 4.14 Bionure
- 4.14.1 Bionure Company Information
- 4.14.2 Bionure Business Overview
- 4.14.3 Bionure Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Bionure Neuroprotective Products Product Portfolio
- 4.14.5 Bionure Recent Developments
- 4.15 Bioniz Theraputics.
- 4.15.1 Bioniz Theraputics. Company Information
- 4.15.2 Bioniz Theraputics. Business Overview
- 4.15.3 Bioniz Theraputics. Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Bioniz Theraputics. Neuroprotective Products Product Portfolio
- 4.15.5 Bioniz Theraputics. Recent Developments
- 4.16 BHR Pharma
- 4.16.1 BHR Pharma Company Information
- 4.16.2 BHR Pharma Business Overview
- 4.16.3 BHR Pharma Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 BHR Pharma Neuroprotective Products Product Portfolio
- 4.16.5 BHR Pharma Recent Developments
- 4.17 Allon therapeutics
- 4.17.1 Allon therapeutics Company Information
- 4.17.2 Allon therapeutics Business Overview
- 4.17.3 Allon therapeutics Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Allon therapeutics Neuroprotective Products Product Portfolio
- 4.17.5 Allon therapeutics Recent Developments
5 Global Neuroprotective Products Market Scenario by Region
- 5.1 Global Neuroprotective Products Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Neuroprotective Products Sales by Region: 2021-2032
- 5.2.1 Global Neuroprotective Products Sales by Region: 2021-2026
- 5.2.2 Global Neuroprotective Products Sales by Region: 2027-2032
- 5.3 Global Neuroprotective Products Revenue by Region: 2021-2032
- 5.3.1 Global Neuroprotective Products Revenue by Region: 2021-2026
- 5.3.2 Global Neuroprotective Products Revenue by Region: 2027-2032
- 5.4 North America Neuroprotective Products Market Facts & Figures by Country
- 5.4.1 North America Neuroprotective Products Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Neuroprotective Products Sales by Country (2021-2032)
- 5.4.3 North America Neuroprotective Products Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Neuroprotective Products Market Facts & Figures by Country
- 5.5.1 Europe Neuroprotective Products Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Neuroprotective Products Sales by Country (2021-2032)
- 5.5.3 Europe Neuroprotective Products Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Neuroprotective Products Market Facts & Figures by Country
- 5.6.1 Asia Pacific Neuroprotective Products Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Neuroprotective Products Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Neuroprotective Products Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Neuroprotective Products Market Facts & Figures by Country
- 5.7.1 South America Neuroprotective Products Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Neuroprotective Products Sales by Country (2021-2032)
- 5.7.3 South America Neuroprotective Products Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Neuroprotective Products Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Neuroprotective Products Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Neuroprotective Products Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Neuroprotective Products Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Neuroprotective Products Sales by Type (2021-2032)
- 6.1.1 Global Neuroprotective Products Sales by Type (2021-2032) & (tons)
- 6.1.2 Global Neuroprotective Products Sales Market Share by Type (2021-2032)
- 6.2 Global Neuroprotective Products Revenue by Type (2021-2032)
- 6.2.1 Global Neuroprotective Products Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Neuroprotective Products Revenue Market Share by Type (2021-2032)
- 6.3 Global Neuroprotective Products Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Neuroprotective Products Sales by Application (2021-2032)
- 7.1.1 Global Neuroprotective Products Sales by Application (2021-2032) & (tons)
- 7.1.2 Global Neuroprotective Products Sales Market Share by Application (2021-2032)
- 7.2 Global Neuroprotective Products Revenue by Application (2021-2032)
- 7.2.1 Global Neuroprotective Products Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Neuroprotective Products Revenue Market Share by Application (2021-2032)
- 7.3 Global Neuroprotective Products Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Neuroprotective Products Value Chain Analysis
- 8.1.1 Neuroprotective Products Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Neuroprotective Products Production Mode & Process
- 8.2 Neuroprotective Products Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Neuroprotective Products Distributors
- 8.2.3 Neuroprotective Products Customers
9 Global Neuroprotective Products Analyzing Market Dynamics
- 9.1 Neuroprotective Products Industry Trends
- 9.2 Neuroprotective Products Industry Drivers
- 9.3 Neuroprotective Products Industry Opportunities and Challenges
- 9.4 Neuroprotective Products Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst